Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Convention Name Might 7, 2025 4:30 PM ET
Firm Contributors
Richard Lepke – Senior Director, Investor Relations
Marianne De Backer – Chief Government Officer
Mark Eisner – Government Vice President & Chief Medical Officer
Jason O’Byrne – Government Vice President & Chief Monetary Officer
Mika Derynck – Government Vice President of Therapeutic Head Oncology
Convention Name Contributors
Gena Wang – Barclays
Paul Choi – Goldman Sachs
Nick Gasic – Leerink Companions
Phil Nadeau – TD Cowen
Patrick Trucchio – H.C. Wainwright & Co.
Joseph Stringer – Needham & Firm
Operator
Hey. Welcome to Vir Biotechnology’s First Quarter 2025 Monetary Outcomes and Enterprise Replace Name. As a reminder, this convention name is being recorded. At the moment, all contributors are in a listen-only mode. After the audio system presentation, there shall be a question-and-answer session.
I’ll now flip the decision over to Wealthy Lepke, Senior Director, Investor Relations. Chances are you’ll start, Mr. Lepke.
Richard Lepke
Thanks and good afternoon. With me at this time are Dr. Marianne De Backer, our Chief Government Officer; Dr. Mark Eisner, our Chief Medical Officer; Jason O’Byrne, our Chief Monetary Officer; and Dr. Mika Derynck, our Government Vice President of Oncology, who shall be out there in the course of the Q&A session.
Earlier than we start, I want to remind everybody that a number of the statements we’re making at this time are forward-looking statements beneath the securities legal guidelines. These forward-looking statements contain substantial dangers and uncertainties that might trigger our medical improvement applications, future outcomes, efficiency or achievements to vary considerably from these expressed or implied by such forward-looking statements. These dangers and uncertainties and dangers related to our enterprise are described within the firm’s studies filed with the Securities and Alternate Fee, together with Varieties 10-Ok, 10-Q and 8-Ok.
I’ll now flip the
